{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:56:18Z","timestamp":1768262178147,"version":"3.49.0"},"reference-count":18,"publisher":"FapUNIFESP (SciELO)","issue":"8","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cad. Sa\u00fade P\u00fablica"],"abstract":"<jats:p>Abstract: This study aimed to estimate the cost-effectiveness of four therapeutic approaches available for mucosal leishmaniasis in Brazil: miltefosine, meglumine antimoniate, combined with and without pentoxifylline, and liposomal amphotericin B. The perspective adopted was that of the Brazilian Unified National Health System (SUS). The outcome of interest was \u201ccured patient\u201d, which was analyzed using a decision tree model. Estimates of direct costs and effectiveness were obtained from the scientific literature. Meglumine antimoniate alone was the base comparator strategy; liposomal amphotericin B showed an incremental cost-effectiveness ratio (ICER) of USD 7,409.13 per cured patient, and the combination of meglumine antimoniate with pentoxifylline presented an ICER of USD 85.13. Miltefosine was absolutely dominated, with higher cost and similar effectiveness when compared to meglumine antimoniate. Sensitivity analyses, varying the cost by \u00b125%, did not change the results. However, when the cost of miltefosine was estimated at less than USD 171.23, this strategy was dominant over meglumine antimoniate alone. The results confirm that treatment with liposomal amphotericin B remains the option with the highest ICER among the approaches analyzed. Miltefosine may be cost-effective based on the variation in the acquisition price, which deserves attention because it is the only available oral option. The non-accounting of other aspects prevent the use of these results immediately to support decision-making, but they point out the need to negotiate the prices of drugs available for mucosal leishmaniasis and indicates the need of encouraging technology transfer or other actions aimed at expanding the performance of the Brazilian national industrial complex.<\/jats:p>","DOI":"10.1590\/0102-311xen132523","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T13:22:39Z","timestamp":1724073759000},"source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness study of therapeutic approaches for mucosal leishmaniasis"],"prefix":"10.1590","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0875-3600","authenticated-orcid":false,"given":"Jana\u00edna de Pina","family":"Carvalho","sequence":"first","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-7403","authenticated-orcid":false,"given":"Gl\u00e1ucia","family":"Cota","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-2651","authenticated-orcid":false,"given":"Mariana Louren\u00e7o","family":"Freire","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5648-3932","authenticated-orcid":false,"given":"Endi Lanza","family":"Galv\u00e3o","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil; Universidade Federal dos Vales do Jequitinhonha e Mucuri,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1087-9819","authenticated-orcid":false,"given":"Sarah Nascimento","family":"Silva","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5682-2981","authenticated-orcid":false,"given":"T\u00e1lia Santana Machado de","family":"Assis","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil; Centro Federal de Educa\u00e7\u00e3o Tecnol\u00f3gica de Minas Gerais,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2024]]},"reference":[{"issue":"11","key":"ref1","article-title":"Leishmanioses.","author":"Maia-Elkhoury ANS","year":"2022","journal-title":"Informe Epidemiol\u00f3gico das Am\u00e9ricas"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0035-9203(86)90243-9","article-title":"Mucosal leishmaniasis (\"espundia\" Escomel, 1911)","volume":"80","author":"Marsden PD","year":"1986","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref3","series-title":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021-2030: overview","year":"2020"},{"key":"ref4","series-title":"Manual de vigil\u00e2ncia da leishmaniose tegumentar americana.","year":"2017","edition":"2nd Ed"},{"key":"ref5","series-title":"Relat\u00f3rio de recomenda\u00e7\u00e3o n\u00ba 365: miltefosina para o tratamento da leishmaniose tegumentar","year":"2018"},{"key":"ref6","series-title":"Nota Informativa n\u00ba 13\/2020-CGZV\/DEIDT\/SVS\/MS. Orienta\u00e7\u00f5es sobre o uso da miltefosina para o tratamento da leishmaniose tegumentar no \u00e2mbito do Sistema \u00danico de Sa\u00fade."},{"key":"ref7","series-title":"Guideline for the treatment of leishmaniasis in the Americas.","year":"2022","edition":"2nd Ed"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010931","article-title":"The cure rate after different treatments for mucosal leishmaniasis in the Americas a systematic review","volume":"16","author":"Carvalho JP","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"ref9","first-page":"143","article-title":"A import\u00e2ncia da avalia\u00e7\u00e3o de tecnologias para o Sistema \u00danico de Sa\u00fade BIS","volume":"14","author":"Elias FTS","year":"2013","journal-title":"Boletim do Instituto de Sa\u00fade"},{"key":"ref10","article-title":"Lei n\u00ba 8.080, de 19 de setembro de 1990. Disp\u00f5e sobre as condi\u00e7\u00f5es para a promo\u00e7\u00e3o, prote\u00e7\u00e3o e recupera\u00e7\u00e3o da sa\u00fade, a organiza\u00e7\u00e3o e o funcionamento dos servi\u00e7os correspondentes e d\u00e1 outras provid\u00eancias.","year":"1990","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref11","article-title":"Lei n\u00ba 12.401, de 28 de abril de 2011. Altera a Lei n\u00ba 8.080, de 19 de setembro de 1990, para dispor sobre a assist\u00eancia terap\u00eautica e a incorpora\u00e7\u00e3o de tecnologia em sa\u00fade no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS.","year":"2011","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0454-2020","article-title":"Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil","volume":"54","author":"Carvalho JP","year":"2021","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref13","series-title":"Leishmaniose tegumentar americana - Casos confirmados notificados no Sistema de Informa\u00e7\u00e3o de Agravos de Notifica\u00e7\u00e3o - Brasil."},{"key":"ref14","series-title":"Diretrizes metodol\u00f3gicas: diretriz de avalia\u00e7\u00e3o econ\u00f4mica.","year":"2014","edition":"2nd Ed"},{"key":"ref15","series-title":"Calculadora do cidad\u00e3o."},{"key":"ref16","series-title":"Conversor de moedas."},{"key":"ref17","series-title":"O uso de limiares de custo-efetividade nas decis\u00f5es em sa\u00fade: recomenda\u00e7\u00f5es da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS","year":"2022"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e2457","DOI":"10.1093\/cid\/ciaa1238","article-title":"Efficacy and tolerability of miltefosine in the treatment of cutaneous leishmaniasis.","volume":"73","author":"Ware JM","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Cadernos de Sa\u00fade P\u00fablica"],"original-title":["Estudo de custo-efetividade das abordagens terap\u00eauticas para leishmaniose mucosa"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0102-311X2024000801403&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T13:22:47Z","timestamp":1724073767000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0102-311X2024000801403&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024]]}},"alternative-id":["S0102-311X2024000801403"],"URL":"https:\/\/doi.org\/10.1590\/0102-311xen132523","relation":{},"ISSN":["1678-4464","0102-311X"],"issn-type":[{"value":"1678-4464","type":"electronic"},{"value":"0102-311X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e00132523"}}